Identification of monoclonal anti-HMW-MAA antibody linear peptide epitope by proteomic database mining.

An efficient strategy is presented for the identification of antigenic sequences in the context of given MHC molecules of interest. The proteomic analysis of the antigenic peptide repertoire is described and demonstrated by using high-molecular weight melanoma-associated antigen. The identification of the epitopic sequence of a monoclonal antibody raised against the 250 kDa tumor associated antigen was reached by using only seven short synthetic peptide fragments, instead of the 155 non-overlapping 15-mer peptides theoretically necessary as minimum screening library. The present result has been obtained by applying as driving criteria the analysis of the peptide affinity to MHC class II molecules and the non-self discrimination concept.

[1]  S. Ferrone,et al.  Idiotypic cascade in the human high molecular weight melanoma‐associated antigen system: Fine specificity and idiotypic profile of anti‐anti‐idiotypic monoclonal antibodies , 1993, European journal of immunology.

[2]  C. Watts,et al.  Control of antigen presentation by a single protease cleavage site. , 2000, Immunity.

[3]  S. Ferrone,et al.  Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. , 1993, Pharmacology & therapeutics.

[4]  P. Itin,et al.  Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[6]  A. Albino,et al.  Biosynthesis and intracellular processing of four human melanoma associated antigens. , 1986, Cancer research.

[7]  S. Stevanović,et al.  Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope , 2003, Peptides.

[8]  Alberta Lucchese,et al.  Monoclonal and polyclonal humoral immune response to EC HER‐2/NEU peptides with low similarity to the host's proteome , 2002, International journal of cancer.

[9]  N. Greenspan,et al.  Dimensions of antigen recognition and levels of immunological specificity. , 2001, Advances in cancer research.

[10]  A. Miller,et al.  Dominance and crypticity of T cell antigenic determinants. , 1993, Annual review of immunology.

[11]  S. Rosenberg,et al.  CD4+CD25+ Suppressor Lymphocytes in the Circulation of Patients Immunized Against Melanoma Antigens , 2003, Journal of immunotherapy.

[12]  Christina Kuttler.  An Algorithm for the Prediction of Proteasomal Cleavages , 2000, German Conference on Bioinformatics.

[13]  V. Engelhard,et al.  Antigens derived from melanocyte differentiation proteins: self‐tolerance, autoimmunity, and use for cancer immunotherapy , 2002, Immunological reviews.

[14]  E. Sercarz,et al.  Determinant spreading and the dynamics of the autoimmune T-cell repertoire. , 1993, Immunology today.

[15]  A. Poole,et al.  Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. , 2003, Arthritis and rheumatism.

[16]  J. Wolchok,et al.  Multiple pathways to tumor immunity and concomitant autoimmunity , 2002, Immunological reviews.

[17]  S. Ferrone,et al.  Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. , 1985, Journal of immunology.

[18]  E. Gilboa.  The risk of autoimmunity associated with tumor immunotherapy , 2001, Nature Immunology.

[19]  Jian Zhang,et al.  The Protein Information Resource: an integrated public resource of functional annotation of proteins , 2002, Nucleic Acids Res..

[20]  Alberta Lucchese,et al.  Individuation of monoclonal anti-HPV16 E7 antibody linear peptide epitope by computational biology , 2001, Peptides.

[21]  S. Ferrone,et al.  Distribution of a cross-species melanoma-associated antigen in normal and neoplastic human tissues. , 1985, The Journal of investigative dermatology.

[22]  R M Zinkernagel,et al.  Localization dose and time of antigens determine immune reactivity. , 2000, Seminars in immunology.

[23]  S. Ferrone,et al.  Higher cytolytic efficiency of an IgG2 alpha than of an IgG1 monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen. , 1982, Cellular immunology.

[24]  R. Dummer,et al.  Non‐self‐discrimination as a driving concept in the identification of an immunodominant HMW‐MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients , 2004, International journal of cancer.

[25]  G. Nossal.  Vaccination and autoimmunity. , 2000, Journal of autoimmunity.

[26]  S. Ferrone,et al.  Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. , 1987, Cancer research.

[27]  B. Longenecker,et al.  Mucin 1-Specific Immunotherapy in a Mouse Model of Spontaneous Breast Cancer , 2003, Journal of immunotherapy.

[28]  P. van Endert,et al.  Efficient MHC class I-independent amino-terminal trimming of epitope precursor peptides in the endoplasmic reticulum. , 2001, Immunity.

[29]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[30]  Jim Miller,et al.  Endosomal proteases and antigen processing. , 1997, Trends in biochemical sciences.

[31]  B. Martoglio,et al.  Intramembrane Proteolysis of Signal Peptides: An Essential Step in the Generation of HLA-E Epitopes1 , 2001, The Journal of Immunology.

[32]  S. Ferrone,et al.  Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. , 1993, Cancer research.